<DOC>
	<DOCNO>NCT00529568</DOCNO>
	<brief_summary>The purpose study assess ability eltrombopag maintain platelet count sufficient facilitate initiation antiviral therapy , minimise antiviral therapy dose reduction avoid permanent discontinuation antiviral therapy . The clinical benefit eltrombopag measure proportion subject able achieve Sustained Virological Response ( SVR ) .</brief_summary>
	<brief_title>Eltrombopag To Initiate And Maintain Interferon Antiviral Treatment To Benefit Subjects With Hepatitis C Liver Disease</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Peginterferon alfa-2b</mesh_term>
	<mesh_term>Antiviral Agents</mesh_term>
	<criteria>Male female subject , &gt; 18 year Evidence chronic hepatitis C virus ( HCV ) infection Subjects appropriate candidate peginterferon ( pegIFN ) ribavirin antiviral therapy A platelet count &lt; 75,000/mcL Haemoglobin &gt; 11.0g/dL men &gt; 10.0g/dL woman Absolute neutrophil count ( ANC ) &gt; 750/mm3 history infection associate neutropenia Creatinine clearance &gt; 50mL/minute All fertile male female must use two form effective contraception treatment 24 week treatment end Subject able understand , consent comply protocol requirement instruction likely complete study plan Exclusion criterion : Nonresponders previous treatment pegIFN ribavirin fail achieve sustain virologic response ( SVR ) reason thrombocytopenia , despite optimal course ( dose duration ) combination therapy pegIFN ribavirin Decompensated liver disease , e.g . ChildPugh score &gt; 6 history ascites hepatic encephalopathy current evidence ascites Known hypersensitivity , intolerance allergy interferon ( IFN ) , ribavirin , eltrombopag ingredient Serious cardiac , cerebrovascular , pulmonary disease would preclude treatment pegIFN ribavirin Subjects history one following : Suicide attempt hospitalisation depression past 5 year Any current severe poorly control psychiatric disorder The following subject eligible study participation , must assess followed ( recommend ) mental health professional : Subjects severe poorly control psychiatric disorder 6 month ago less 5 year ago Seizure disorder well control History clinically significant bleed oesophageal gastric varix Subjects haemoglobinopathy , e.g . sickle cell anaemia , thalassemia major Any prior history arterial venous thrombosis AND two follow risk factor : hereditary thrombophilic disorder ( e.g . Factor V Leiden , ATIII deficiency , etc ) , hormone replacement therapy , systemic contraception ( contain estrogen ) , smoke , diabetes , hypercholesterolemia , medication hypertension cancer Preexisting cardiac disease ( New York Heart Association ( NYHA ) Grade III/IV ) , arrhythmias know involve risk thromboembolic event , correct QT interval ( QTc ) &gt; 450 msec Evidence hepatocellular carcinoma Laboratory evidence infection human immunodeficiency virus ( HIV ) active Hepatitis B Virus ( HBV ) infection Any disease condition associate active bleeding require anticoagulation heparin warfarin Therapy antineoplastic immunomodulatory treatment &lt; 6 month prior first dose eltrombopag . Subjects malignancy diagnose and/or treat within past 5 year , except subject localise basal squamous cell carcinoma treat local excision subject malignancies adequately treat , opinion oncologist , excellent chance cancerfree survival Pregnant nursing woman Males female partner pregnant History alcohol/drug abuse dependence within 6 month study start ( unless participate control rehabilitation programme ) Treatment investigational drug IFN within 30 day 5 halflives ( whichever longer ) screen visit History platelet clump prevents reliable measurement platelet count History major organ transplantation exist functional graft Thyroid dysfunction adequately control Subjects plan cataract surgery Evidence portal vein thrombosis abdominal imaging within 3 month baseline visit</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2013</verification_date>
	<keyword>hepatitis C</keyword>
	<keyword>ribavirin</keyword>
	<keyword>Hepatitis C-related thrombocytopenia</keyword>
	<keyword>thrombopoietin</keyword>
	<keyword>peginterferon alfa-2b</keyword>
	<keyword>platelet</keyword>
</DOC>